New drug combo tested for Tough-to-Treat lung cancer
NCT ID NCT05401110
Summary
This early-stage study aims to find a safe and effective dose when combining two drugs (osimertinib and carotuximab) for people with advanced lung cancer that has a specific genetic change (EGFR mutation). Researchers will enroll 60 adults whose cancer has progressed despite previous treatments. The main goal is to determine how much of the drug combination patients can tolerate while monitoring for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Cancer at Beverly Hills (THO)
RECRUITINGBeverly Hills, California, 90211, United States
Contact
-
Cedars-Sinai Cancer at Hunt Cancer Center - TMPNCC
RECRUITINGTorrance, California, 90505, United States
Contact
-
Cedars-Sinai Cancer at SOCC
RECRUITINGLos Angeles, California, 90048, United States
Contact
-
Cedars-Sinai Cancer at The Angeles Clinic and Research Institute
RECRUITINGLos Angeles, California, 90025, United States
Contact
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.